Moderate Evidence
Research Overview
Oveporexton Research for Narcolepsy Type 1
An evidence-based overview of research examining Oveporexton in the context of narcolepsy type 1. This page synthesizes findings from peer-reviewed literature.
Research Summary
Oveporexton is specifically developed for NT1, caused by autoimmune destruction of orexin-producing neurons. Phase 3 ORCHESTRA-NT1 trial demonstrated significant improvements in ESS, cataplexy frequency, and MWT. FDA Breakthrough Therapy designation granted 2021.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Oveporexton may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.